PSC
AEGR

Piper Sandler & Co’s Aegerion Pharmaceuticals AEGR Stock Holding History

Piper Sandler & Co’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-18,000
Closed -$471K – 139
2015
Q1 		$471K Buy
+18,000
New +$458K 0.2% 48

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Piper Sandler & Co's AEGR Position: Q2 2015 in Review

Piper Sandler & Co sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2015, closing a stake of 18,000 shares — an estimated $471K sold.

Piper Sandler & Co first reported a position in AEGR in Q1 2015 and held it in 1 quarter. The position peaked at $471K in Q1 2015. 97 funds tracked by Wall St. Rank hold AEGR as of Q2 2015.

  • Piper Sandler & Co reported no remaining Aegerion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 18,000 Aegerion Pharmaceuticals shares in Q2 2015, an estimated $471K.
  • Piper Sandler & Co first reported a position in Aegerion Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Piper Sandler & Co's Aegerion Pharmaceuticals position peaked at $471K in Q1 2015.
  • 97 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2015.

Based on Piper Sandler & Co's 13F filing for Q2 2015, filed 14 Aug 2015.